Petmed Express Inc

Petmed Express Inc

  • Price (EUR)14.99
  • Today's Change-0.68 / -4.34%
  • Shares traded0.00
  • 1 Year change-38.89%
  • Beta--
Data delayed at least 15 minutes, as of Mar 23 2023.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

PetMed Express, Inc. is a pet pharmacy, which is engaged in delivering prescription and non-prescription pet medications and other health products for dogs, cats and horses through its website at petmeds.com, as well as through its toll-free number. The Company's product line contains approximately 3,000 SKUs of pet medications, health products, and supplies. It offers various pet supplies, including food, beds, crates, stairs and other pet supplies. The Company's products include Non-Prescription Medications (OTC) and supplies, and Prescription Medications (Rx). OTC and supplies include flea and tick control products, bone and joint care products, vitamins, treats, nutritional supplements, hygiene products, and supplies. Rx includes heartworm and flea and tick preventatives, arthritis, dermatitis, thyroid, diabetes, pain medications, heart/blood pressure, and other specialty medications, as well as generic substitutes.

  • Revenue in USD (TTM)260.45m
  • Net income in USD11.40m
  • Incorporated1996
  • Employees212.00
  • Location
    Petmed Express Inc420 South Congress AvenueDELRAY BEACH 33445United StatesUSA
  • Phone+1 (561) 426-4444
  • Fax+1 (800) 600-8285
  • Websitehttps://www.1800petmeds.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
PETS:NSQ since
PetCareRx IncAnnounced17 Jan 202317 Jan 2023Announced-13.49%--
Data delayed at least 15 minutes, as of Mar 24 2023 19:59 BST.
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.